Clinical Trial Update: Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of rhPro-UK thrombolysis given 4.5-6 hours after acute ischemic stroke; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• rhPro-UK (recombinant human pro-urokinase)

Snippet

Sponsor: Tasly Biopharmaceuticals Co., Ltd. | Conditions: Acute Ischaemic Stroke | Phase 3 | Status: COMPLETED